<DOC>
	<DOC>NCT00413023</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).</brief_summary>
	<brief_title>Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Inclusion criteria: Primary diagnosis of Major depressive Disorder as defined in DSMIV. Capable of giving informed consent and willing to comply with the study requirements. Women of childbearing potential must agree to one of a number of defined acceptable methods of birth control. Primary diagnosis within the past 6 months of another Axis 1 disorder such as an anxiety disorder. Use of medications for a psychiatric condition including herbals in the past 212 weeks according to medication type. Subjects who, in the investigator's judgement, pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months. Subjects who currently meet or who met within 6 months prior to screening DSMIV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSMIV criteria for substance dependence (other than nicotine). Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>major depressive disorder</keyword>
	<keyword>MDD</keyword>
</DOC>